| Patent application number | Description | Published |
|---|
| 20110200686 | COMPOSITIONS OF MODULATORS OF THE WNT/B-CATENIN PATHWAY AND AN N-CINNAMYL-N'BENZHYDRYL PIPERAZINE AND THEIR USE IN TREATING NEOPLASTIC CONDITIONS INCLUDING MALIGNANT MELANOMA - The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating a neoplastic condition in a subject by administering the modulator of the Wnt/βcatenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof to the subject under conditions effective to treat a neoplastic disorder. | 08-18-2011 |
| 20110293750 | ACTIVATED WNT-BETA-CATENIN SIGNALING IN MELANOMA - The present invention is directed to a method of determining the prospects for survival of a melanoma patient. This method involves providing a biological sample from a patient diagnosed with melanoma, determining the level of an indicator of Wnt/β-catenin activation in the sample, comparing the level of the indicator of Wnt/β-catenin activation in the sample against a standard level of the indicator of Wnt/β-catenin activation correlated to survival of melanoma, and determining a patient's prospects for survival of melanoma based on the comparison. The present invention also relates to a method of improving survival of melanoma patients, decreasing metastases in melanoma patients, decreasing proliferation of cancer cells in melanoma patients, decreasing melanoma recurrence in melanoma patients, and/or decreasing tumor size in melanoma patients. This involves selecting melanoma patients and subsequently determining and monitoring therapy based on their level of Wnt/β-catenin activation. The selected melanoma patients are treated with a dose of an activator or synergizer of Wnt/β-catenin based on the patient's level of Wnt/β-catenin, under conditions effective, respectively, to improve survival of the selected melanoma patients, to decrease metas-tases in the selected melanoma patients, to decrease proliferation of cancer cells in the selected melanoma patients, to decrease melanoma recurrence in the selected melanoma patients, and/or to decrease tumor size in the selected melanoma patients. | 12-01-2011 |
| Patent application number | Description | Published |
|---|
| 20080204966 | Controlled Transport and Assembly of Nanostructures - Systems and methods for manipulating nanostructures, such as nanospheres, nanodisks, nanowires, and nanotubes. The systems and methods permit the construction of nano-scale contacts, scaffolds, and motors using electric fields that do not require the use of toxic nanostructure materials. The electric fields are imposed on the nanostructures using electrodes having specific shapes and driven with voltages having particular amplitudes, frequencies, and phase differences. The electrode shape and voltage characteristics influence the configuration of the electric fields, which in turn influences the ultimate configuration of the nanostructures. The nanostructures retain their configuration after the electric fields and any transport medium, such as deionized water, are removed. | 08-28-2008 |
| 20090146767 | Ferromagnetic Nanorings, Mediums Embodying Same Including Devices and Methods Related Thereto - Featured is a magnetic ring structure including at least a vortex magnetic state such as symmetrically and asymmetrically shaped nanorings, having small diameters (e.g., on the order of 100 nm). In particular embodiments, the width and thickness of the asymmetrical nanorings varies as a function of the locations on the circumference so that maxima and minima thereof are located on opposite sides of the nanoring. Also featured are methods for fabricating such symmetrically and asymmetrically shaped nanorings. Also featured are methods for controlling the reversal process so as to thereby create vortex states in such asymmetric nanorings by controlling the field angle. | 06-11-2009 |
| 20110311791 | SYSTEM AND METHOD FOR PRECISION TRANSPORT, POSITIONING, AND ASSEMBLING OF LONGITUDINAL NANO-STRUCTURES - A method for assembling multi-component nano-structures that includes dispersing a plurality of nano-structures in a fluid medium, and applying an electric field having an alternating current (AC) component and a direct current (DC) component to the fluid medium containing the plurality of nano-structures. The electric field causes a first nano-structure from the plurality of nano-structures to move to a predetermined position and orientation relative to a second nano-structure of the plurality of nano-structures such that the first and second nano-structures assemble into a multi-component nano-structure. | 12-22-2011 |
| 20110315656 | FERROMAGNETIC NANORINGS, MEDIUMS EMBODYING SAME INCLUDING DEVICES AND METHODS RELATED THERETO - Featured is a magnetic ring structure including at least a vortex magnetic state such as symmetrically and asymmetrically shaped nanorings, having small diameters (e.g., on the order of 100 nm). In particular embodiments, the width and thickness of the asymmetrical nanorings varies as a function of the locations on the circumference so that maxima and minima thereof are located on opposite sides of the nanoring. Also featured are methods for fabricating such symmetrically and asymmetrically shaped nanorings. Also featured are methods for controlling the reversal process so as to thereby create vortex states in such asymmetric nanorings by controlling the field angle. | 12-29-2011 |
| Patent application number | Description | Published |
|---|
| 20100239502 | IN VIVO EXPRESSION ANALYSIS USING ULTRASOUND-INDUCED TRANSFECTION OF REPORTER CONSTRUCTS - The invention features compositions and methods for in vivo expression analysis. The data presented herein demonstrates that ultrasound-enhanced delivery and/or expression of a composition for expression analysis comprising microbubbles vectors as well as a genetic payload, comprising a “always-on” promoter, a “reference” reporter gene, a “query” promoter and an “answer” reporter gene, enables in vivo analysis of gene expression both without requiring prior preparation (especially genetic modification) of the test subject (animal or patient) and without causing long term or systemic effects on the subject. Such an invention can be used, for example, to query the epigenotypic or phenotypic response of the individual subject to a foreign effector substance such as a pyrogen, pharmaceutical compound, pharmaceutical lead compound, an allergen, an autoimmunogene, a toxin, a polyclonal antibody, a monoclonal antibody, an antigen, a lipid, a carbohydrate, a peptide, a protein, a protein-complex, an amino acid, a fatty acid, a nucleotide, DNA, RNA, PNA, siRNA and micro RNA. | 09-23-2010 |
| Patent application number | Description | Published |
|---|
| 20080294202 | Bone Anchor With Locking Cap and Method of Spinal Fixation - A bone anchor ( | 11-27-2008 |
| 20100185290 | FLEXIBLE CHAIN IMPLANTS AND INSTRUMENTATION - A flexible chain implant for insertion into an interior volume of a vertebral body. The implant may be implanted in an insertion position for sliding through a cannula and is flexible for packing into the interior volume in an implanted configuration. The implant randomly separates in the implanted configuration. The implant includes a top member and a bottom member, wherein the top and bottom members are coupled to one another at a coupled portion. The top and bottom members preferably each include an inner surface such that the inner surfaces include a plurality of alternating projections and recesses so that the projections are received within the recesses in an insertion position. Alternatively, the implant may include a plurality of substantially non-flexible bodies and a plurality of substantially flexible links interconnecting the bodies. The non-flexible bodies include a plurality of facets and/or abutment surfaces. | 07-22-2010 |
| 20110144766 | Allograft Bone Plugs, Systems and Techniques - The present invention provides a system, device, instruments and methods for inserting and/or improving the holding strength and purchase of a bone screw, bone pin, or bone dowel in bone. Embodiments include monolithic allograft tissue forms, multi-piece allograft tissue forms, distally expandable portions, partially and fully demineralized portions, and flexible connecting portions. Advantages of the allograft tissue forms of the present invention include improved pedicle screw blackout strength and improved filling of bone voids. Methods for making and instruments and techniques for inserting the augmentation device, system and screws or pins are also disclosed. | 06-16-2011 |
| Patent application number | Description | Published |
|---|
| 20090181665 | SYSTEMS AND METHODS FOR REAL-TIME SERVICE ASSURANCE - A system and methods for providing service assurance using real-time monitoring, management and maintenance capabilities to provide customers and vendors with information related to the state of the service. The service assurance domain implements end-to-end functionality with a level of granularity sufficient to diagnose issues to the device and call/session level. | 07-16-2009 |
| 20100120382 | Systems and Methods for Dampening TDMA Interference - Systems and methods are disclosed which relate to mitigating the detrimental effects of interference to electronic devices from mobile telephones utilizing any form of time-domain multiplexing technology. A wireless transmitter inside the mobile telephone broadcasts a warning transmission which can be received by affected devices. Once the warning transmission is received by an affected device, the device activates a blanking circuit comprising an actuator and a switch or switches. The switches open for the duration of the interference so that the user does not receive undesired output such as: noise through a speaker, noise through a microphone, or other interference with electrical signals. | 05-13-2010 |
| 20110296154 | Automated Communication Configuration - A method for use at a user device of a communications network include utilizing a configuration file obtained from a remote device to configure a communication of an application executed at the user device without requiring user input, the configuration file including logic applied by the application to identify, from a plurality of data bearers available to the user device, a select data bearer for use in conducting the communication based on one or more parameters representative of the current operational context of the user device. The user device includes a storage module to store a configuration file obtained from a remote device and a processing module to execute an application, wherein during execution the application is to utilize logic of configuration file to identify, from a plurality of data bearers available to the user device, a select data bearer for use in conducting a communication of the application. | 12-01-2011 |
| Patent application number | Description | Published |
|---|
| 20100158512 | Centrally Managed, Self-Survivable Wavelength Division Multiplexed Passive Optical Network - A centrally-managed, colorless, bi-directional wavelength division multiplexed passive optical network (WDM-PON) architecture. The WDM-PON architecture is self-survivable, and can protect network failures in, for example, distribution/feeder fiber, remote node and laser failure. The WDM-PON architecture requires only N-wavelength channels for N optical network units. | 06-24-2010 |
| 20100278538 | MILLIMETER WAVE WIRELESS COMMUNICATION SYSTEM - A wireless communication system adapted to transmit data between two locations, for example between a plurality of processors and memory. Digitally coded millimeter waves can be used to transfer data between antenna arrays. A global optical clock can provide network coherence, frequency self-tracking, and a local oscillator signal for data digital symbol coding/decoding and symbol up-down conversion to/from the millimeter wavelength carrier. | 11-04-2010 |
| 20110206383 | SYSTEMS AND METHODS FOR PROVIDING AN OPTICAL INFORMATION TRANSMISSION SYSTEM - The present invention describes systems and methods of providing optical information transmission systems. An exemplary embodiment of the present invention includes a precoder configured to differentially encode a binary data signal, a duobinary encoder configured to encode the differentially encoded binary data signal as a three-level duobinary signal, an electrical-to-optical conversion unit configured to convert the three-level duobinary signal into a two-level optical signal, and an optical upconversion unit configured to modulate the two-level optical signal onto a higher frequency optical carrier signal and transmit the modulated higher frequency optical carrier signal onto an optical transmission medium. | 08-25-2011 |
| Patent application number | Description | Published |
|---|
| 20090137773 | Production Processes and Systems, Compositions, Surfactants, Monomer Units, Metal Complexes, Phosphate Esters, Glycols, Aqueous Film Forming Foams, and Foam Stabilizers - Compositions and methods for making compositions such as RF(Rτ)nQ are provided. The RF group can include at least two —CF3 groups, the Rτ group can be a group having at least two carbons, n can be at least 1, and the Q group can include one or more atoms of the periodic table of elements. RF-intermediates (RF(RT)nQg); Surfactants (RF(RT)nQs); Foam stabilizers (RF(RT)IIQFS); Metal complexes (RF(RT)IIQMC); Phosphate ester (RF(RT)HQPE); Polymers (RF(RT)IIQMU); Monomers (RF(RT)IIQM); Urethanes (RF(Rτ)nQu); and/or Glycols (RF(RT)IIQH) and methods for making the same are provided. | 05-28-2009 |
| 20110213113 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM | 09-01-2011 |
| 20120071689 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS - Production processes and systems are provided that include reacting halogenated compounds, dehalogenating compounds, reacting alcohol's, reacting olefins and a saturated compounds, reacting reactants having at least two —CF | 03-22-2012 |
| Patent application number | Description | Published |
|---|
| 20100166714 | CARDIOVASCULAR STEM CELLS, METHODS FOR STEM CELL ISOLATION, AND USES THEREOF - The present invention relates to isolation of cardiovascular stem cells, and more particularly to cardiovascular stem cells positive for markers isll | 07-01-2010 |
| 20100210713 | REGENERATION AND SURVIVAL OF CARDIAC PROGENITORS AND CARDIOMYOCYTES WITH A STRETCH ACTIVATED TRANSCRIPTION FACTOR - The present invention relates generally to the field of cardiovascular repair, and more particularly to methods and compositions for the survival of cells in response to mechanical stress and to the proliferation of postnatal cardiomyocytes. The present invention relates to a nuclear form of Creb312(N) polypeptide which when expressed in a cell promotes cell survival in response to stress such as mechanical stretch stress. Another aspect of the invention relates to the expression of the nuclear form of Creb312(N) polypeptide in a cardiomyocyte promotes propagation or regeneration of the cardiomyocyte. Other aspect relates to methods and compositions for gene therapy for the treatment of cardiac diseases and disorders in a subject comprising increasing the expression of Creb312(N) polypeptide in cells in vivo or ex vivo, such as cardiac cells and cardiac progenitor cells, and in some embodiments, subsequent transplantation of the Creb312 expressing cells into a subject for the treatment of cardiac diseases and disorders in the subject. | 08-19-2010 |
| 20110033430 | METHODS FOR THE INDUCTION OF A CELL TO ENTER THE ISLET 1+ LINEAGE AND A METHOD FOR THE EXPANSION THEREOF - The present invention relates to methods for the induction and a cell to enter the Islet 1 | 02-10-2011 |
| 20120009158 | VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF - The present invention generally relates to methods and compositions to generate a secondary iPS (2iPS) cell to produce somatic cells of a rare differentiation cell type fate. In some embodiments, the method relates to an increase in efficiency of differentiation and production of high yields of somatic cells of a rare differentiation cell type fate produced from secondary iPS (2iPS) cells as compared to their differentiation from other pluripotent stem cell sources such as ES cells or primary iPS cells. In some embodiments, the present invention relates to compositions, methods and systems for reprogramming a first somatic cell into a primary iPS cell, where the primary iPS cell is then differentiated along a selected linage to produce a second somatic cell, which is then reprogrammed to a secondary iPS cell (2iPS) cell. The 2iPS cell has a high efficiency of differentiating into a cell of the same cell type as the second somatic cell, e.g., a somatic cells of a rare differentiation cell type fate such as but not limited to a ventricular cardiomyocyte, a pancreatic β-cell or a hepatic cell. In some embodiments, the first somatic cell is a fibroblast, or a cardiac cell, but is not limited to cardiac fibroblast cells. In some embodiments, the present invention relates to compositions, methods and systems to produce ventricular cardiomyocytes from secondary induced pluripotent stem cells (iPSC), where the iPSC are themselves generated from ventricular cardiomyocytes. The secondary iPS (2iPS) cell generated from ventricular cardiomyocytes have a higher cardiomyogenic potential and high cardiomyogenic yield as compared to primary iPSC, and are useful in drug discovery, disease modeling and cell-based therapy. | 01-12-2012 |
| 20120027807 | TISSUE ENGINEERED MYOCARDIUM AND METHODS OF PRODUCTION AND USES THEREOF - The present invention generally relates to a population of committed ventricular progenitor (CVP) cells and their use to generate a tissue engineered myocardium, in particular two dimensional tissue engineered myocardium which is comparable to functional ventricular heart muscle. One embodiment of present invention provides a composition and methods for the production of a tissue engineered myocardium which has functional properties of cardiac muscle, such as contractibility (e.g. contraction force) and numerous properties of mature fully functional ventricular heart muscle tissue. In particular, in one embodiment, a composition comprising the tissue engineered myocardium comprises committed ventricular progenitor (CVP) cells seeded on a free-standing biopolymer structure to form functional ventricular myocardium tissue. | 02-02-2012 |
| 20120135051 | GENERATION OF VASCULARIZED HUMAN HEART TISSUE AND USES THEREOF - The present invention relates to the generation of vascularized human heart tissue from human primordial Islet1-positive (ISL1+) progenitors, and more particularly the generation of vascularized human heart tissue from human primordial Islet1+ cardiovascular stem cells which are positive for markers ISL1+/NKX2.5−/KDR−. One aspect of the invention relates to isolation of human ISL1+ primordial cells from human pluripotent cells, such as human ES cells or other human pluripotent stem cell sources, wherein the human ISL1+ primordial cells can differentiate into three different lineages; cardiomyocyte lineages, endothelial lineages and smooth muscle lineages. Another aspect relates to use and implantation of the human primordial ISL1+ progenitors into an animal model to generate human vascularized heart tissue, and more particularly, the production of an in vivo humanized model of vascular disease. One embodiment relates to the use of an in vivo humanized model of vascular disease as an assay, for example to assess drug toxicity and/or identify agents which increase and decrease coronary blood flow to the human vascularized heart tissue. Another embodiment relates to the therapeutic use of human primordial ISL1+ progenitors, for example, in one embodiment the invention provides methods for the treatment cardiovascular disorders and/or congenital heart disease in a subject comprising transplanting into subjects vascularized human heart tissue generated from human ISL1+ progenitors. | 05-31-2012 |
| Patent application number | Description | Published |
|---|
| 20090040453 | Method of plasma beam bombardment of aligning films for liquid crystals - Methods for treating aligning substrates produces uniform alignment of liquid crystals in at least two modes. The method is based on the treatment of liquid crystal aligning substrates with a collimated or partially collimated plasma beam. In one embodiment, the method comprises a step of bombarding an aligning substrate with at least one plasma beam from a plasma beam source at a designated incident angle to align the atomic/molecular structure or the surface profile of the aligning substrate in at least one aligned direction. | 02-12-2009 |
| 20090152772 | METHOD OF FABRICATING ELECTRO-OPTICAL DEVICES WITH POLYMER-STABILIZED LIQUID CRYSTAL MOLECULES - In a preparation method, a chiral or cholesteric liquid crystal, a photoreactive monomer, and a photoinitiator are disposed in a liquid crystal cell. A principal surface of the liquid crystal cell is illuminated with ultraviolet light selected to have a non-uniform ultraviolet light intensity profile in the liquid crystal cell. The illuminating cooperates with the photoinitiator to polymerize at least a portion of the photoreactive monomer near the principal surface to generate a polymer network having a density corresponding to the non-uniform ultraviolet light intensity profile. The polymer network biases the liquid crystal toward a selected helical alignment direction. In some embodiments, the illuminating includes illuminating with first and second ultraviolet light intensity profiles to produce surface and volume polymer network components. | 06-18-2009 |
| 20100002177 | LIQUID CRYSTAL ALIGNMENT USING INKJET PRINTED POLYMERS - A method of preparing liquid crystal alignment films using an inkjet printer to control liquid crystal alignment is disclosed. The alignment ink is formulated from a single alignment material or combination of alignment materials to realize desired pretilt angle. The alignment films can be applied with designed patterns of alignment films of different pretilt angle on at least one substrate to achieve pattern-aligned liquid crystal devices. | 01-07-2010 |
| 20100051194 | POLYMER ENHANCED CHOLESTERIC ELECTRO-OPTICAL DEVICES - The present invention provides liquid crystal devices comprised of a composite of an internal polymer network localized on the substrate surfaces and short-pitch dual-frequency switchable cholesteric liquid crystal that operate in two different modes including in-plane switching (amplitude modulation) and out-of-plane switching (phase modulation). The invention further provides a method of making a liquid crystal device demonstrating uniform lying helical axis where the device comprises a composite of an internal spatially ordered polymer network localized by in-situ photo-polymerization at the surface of the substrate. The invention can be used for flat panel displays, as well as spatial light modulators for applications such as optical waveguides, optical beam scanners, computer-generated holograms, and adaptive optics. | 03-04-2010 |
| 20100315568 | Liquid crystal devices and methods providing fast switching mode - A liquid crystal device includes carbon nanotube-doped liquid crystal materials that have a fast switching mode. The liquid crystals may be nematic liquid crystals contained in an optically controlled birefringence cell, with a small amount of nanotubes relative to the liquid crystals. The cell may operate between an optical bend state and homeotropic state, where the liquid crystals aligning in a bend state in response to low voltage and transform to a homeotropic state in response to high voltage. The cell may capable of a large change in effective birefringence, or variable effective birefringence enabling self-compensated optical retardation. The liquid crystals may be included with an electro-optical film, which may be formed with polymer encapsulated liquid crystals with the inclusion of at least a small amount of nanotubes sufficient to induce homogeneous liquid crystal dispersion. The electro-optical film may be fabricated by lamination or otherwise onto a substrate. | 12-16-2010 |
| 20100315585 | Electro-optical device and method for controlling color - The present invention provides an electro-optical device comprising a cell of polymer-stabilized blue phase (PSBP) liquid crystal under an electrical field and a method of controlling the reflection and transmission of an incident electromagnetic radiation such as visible light, by way of controlling the electrical field. The invention exhibits merits such as cost-effectiveness; simpler manufacturability due to the removal of requirements of polarizer and color filter; and fast switching, among others. | 12-16-2010 |
| 20110007260 | Liquid crystal composition and device thereof - The invention provides a liquid crystal (LC) composition, a LC cell thereof, and a LC device thereof. The LC composition comprises (i) a mixture of two or more nematic liquid crystals, and (ii) at least one chiral dopant. The mixture of the liquid crystals can exist in a blue phase within a temperature range of from about 12-60° C. such as 21-28° C. The LC device can be a blue phase mode liquid crystal display (HPLCD) based on such a room-temperature blue phase LC. The HPLCD requires no alignment, and it exhibits merits such as a fast switching time (e.g. sub-millisecond), a low switching voltage and a large field-induced birefringence, among others. | 01-13-2011 |
| Patent application number | Description | Published |
|---|
| 20090311312 | Transdermal Hormone Delivery System: Compositions And Methods - A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed. | 12-17-2009 |
| 20090324697 | TRANSDERMAL HORMONE DELIVERY SYSTEM: COMPOSITIONS AND METHODS - A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed. | 12-31-2009 |
